Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886.

Lancet Oncol. 2006 Jun;7(6):472-9.

PMID:
16750497
2.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
3.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
4.

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.

Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR.

Urology. 2001 Aug;58(2 Suppl 1):56-64. Review.

PMID:
11502450
5.
6.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

7.

The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.

Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG.

Eur Urol. 2014 Aug;66(2):191-9. doi: 10.1016/j.eururo.2013.05.033. Epub 2013 May 22. Review.

PMID:
23735200
8.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.

PMID:
17404365
9.

The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.

Lubeck DP, Grossfeld GD, Carroll PR.

Urology. 2001 Aug;58(2 Suppl 1):94-100. Review.

PMID:
11502459
10.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.

Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Review.

PMID:
23628492
11.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
12.

Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.

Kunath F, Keck B, Rücker G, Motschall E, Wullich B, Antes G, Meerpohl JJ.

BMC Cancer. 2013 Mar 19;13:131. doi: 10.1186/1471-2407-13-131. Review.

13.

Androgen deprivation for prostate cancer: when and how, the good and the bad.

Chi KN, Nguyen PL, Higano CS.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e176. Review.

14.

[Androgen deprivation for advanced prostate cancer].

Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH.

Urologe A. 2008 Mar;47(3):270-83. doi: 10.1007/s00120-008-1636-2. Review. German.

PMID:
18273599
15.

Intermittent versus continuous androgen deprivation therapy.

Higano CS.

J Natl Compr Canc Netw. 2014 May;12(5):727-33. Review.

PMID:
24812139
16.

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Botrel TE, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, Borges Dos Reis R.

PLoS One. 2016 Jun 16;11(6):e0157660. doi: 10.1371/journal.pone.0157660. eCollection 2016. Review.

17.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

18.

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.

Eur Urol. 2016 Apr;69(4):563-73. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Review.

19.

Medical treatment for biochemical relapse after radiotherapy.

Quero L, Hennequin C.

Cancer Radiother. 2014 Oct;18(5-6):540-4. doi: 10.1016/j.canrad.2014.06.007. Epub 2014 Aug 30. Review.

PMID:
25179255
20.

[Treatment of metastatic cancer of the prostate].

Fournier G, Mangin P.

Presse Med. 1995 Oct 28;24(32):1465-70. Review. French.

PMID:
8545343

Supplemental Content

Support Center